Veradermics raised $256.3 million in an upsized IPO on February 4, 2026, selling 15.1 million shares at $17 per share, above the expected range of $14-$16. 1 3 5 The IPO priced higher than anticipated, with shares soaring 122% to close at $137.65 on debut, signaling strong investor demand. 2 Proceeds will fund Phase II/III clinical trials for VDPHL-01, an oral, non-hormonal extended-release minoxidil formulation for pattern hair loss in men and women. 1 2 3 The New Haven, CT-based company, founded in 2019, trades on the NYSE under ticker MANE and targets FDA approval via 505(b)(2) NDA. 2 3 Pattern hair loss affects ~50 million men and 30 million women in the US, representing a $9 billion market opportunity. 2 3 Anchor investors included Wellington Management ($30M) and Eli Lilly (4.9% of shares). 3 Sources: 1. https://www.bioworld.com/articles/728557-hair-loss-drugmaker-veradermics-floats-upsized-256m-us-ipo 2. https://news.crunchbase.com/public/veradermics-shares-soar-...
- Get link
- X
- Other Apps